A. J. Camm, G. Lip, D. Caterina, R. Savelieva, I. Atar et al.,

, Focused Update of ESC Guidelines for the Management of Atrial Fibrillation, Eur Heart J, vol.33, issue.21, pp.2719-2766, 2012.

S. Björck, B. Palaszewski, L. Friberg, and L. Bergfeldt, Atrial Fibrillation, Stroke Risk, and Warfarin Therapy Revisited, Stroke, vol.44, issue.11, pp.3103-3111, 2013.

P. Kirchhof, S. Benussi, D. Kotecha, A. Ahlsson, D. Atar et al., guidelines for the management of atrial fibrillation, developed in collaboration with EACTS, Eur Heart J, vol.37, issue.38, pp.2893-962, 2016.

D. Kotecha, J. Holmes, H. Krum, D. G. Altman, L. Manzano et al., Efficacy of ? blockers in patients with heart failure plus atrial fibrillation: an individualpatient data meta-analysis. The Lancet, vol.384, pp.2235-2278, 2014.

H. Heidbuchel, P. Verhamme, M. Alings, M. Antz, W. Hacke et al.,

, European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. EP Eur, vol.15, pp.625-51, 2013.

S. J. Connolly, M. D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren et al.,

, Dabigatran versus Warfarin in Patients with Atrial Fibrillation, N Engl J Med, vol.361, issue.12, pp.1139-51, 2009.

M. R. Patel, K. W. Mahaffey, J. Garg, G. Pan, D. E. Singer et al., Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation, N Engl J Med, vol.365, issue.10, pp.883-91, 2011.
URL : https://hal.archives-ouvertes.fr/hal-01038111

C. B. Granger, J. H. Alexander, J. Mcmurray, R. D. Lopes, E. M. Hylek et al., Apixaban versus Warfarin in Patients with Atrial Fibrillation, N Engl J Med, vol.365, issue.11, pp.981-92, 2011.

T. A. Zelniker, C. T. Ruff, S. D. Wiviott, J. Blanc, R. Cappato et al.,

, Edoxaban in atrial fibrillation patients with established coronary artery disease: Insights from ENGAGE AF-TIMI 48, Eur Heart J Acute Cardiovasc Care, 2018.

N. Telles-garcia, K. Dahal, C. Kocherla, G. Lip, P. Reddy et al., Nonvitamin K antagonists oral anticoagulants are as safe and effective as warfarin for cardioversion of atrial fibrillation: A systematic review and meta-analysis, Int J Cardiol, vol.268, pp.143-151, 2018.

A. Dogliotti, E. Paolasso, and R. P. Giugliano, Current and new oral antithrombotics in non-valvular atrial fibrillation: a network meta-analysis of 79 808 patients, Heart, vol.100, issue.5, pp.396-405, 2014.

P. Sardar, S. Chatterjee, S. Chaudhari, and G. Lip, New Oral Anticoagulants in Elderly Adults: Evidence from a Meta-Analysis of Randomized Trials, J Am Geriatr Soc, vol.62, issue.5, pp.857-64, 2014.

Z. Harel, M. Sholzberg, P. S. Shah, K. Pavenski, S. Harel et al., Comparisons between Novel Oral Anticoagulants and Vitamin K Antagonists in Patients with CKD, J Am Soc Nephrol, vol.25, issue.3, pp.431-473, 2014.

M. H. Ellis, Bleeding in patients with atrial fibrillation treated with dabigatran, rivaroxaban or warfarin: A retrospective population-based cohort study, vol.33, pp.55-64, 2016.

I. Hernandez, S. H. Baik, A. Piñera, and Y. Zhang, Risk of Bleeding With Dabigatran in Atrial Fibrillation, JAMA Intern Med, vol.175, issue.1, pp.18-24, 2015.

D. Farmakis, P. Davlouros, G. Giamouzis, G. Giannakoulas, A. Pipilis et al., Direct Oral Anticoagulants in Nonvalvular Atrial Fibrillation: Practical Considerations on the Choice of Agent and Dosing, Cardiology, vol.140, pp.126-158, 2018.

, L'Assurance Maladie. Nouveaux anti-coagulants oraux : une étude de l'Assurance Maladie souligne la dynamique forte de ces nouveaux médicaments et la nécessité d'une vigilance accrue dans leur utilisation

S. Sociale, , 2013.

. Co_def and . Pdf,

B. Bonnamour, Vécu des patients en fibrillation auriculaire sous antocoagulants oraux

P. Garcia, D. A. Lopes, R. D. Hylek, and E. M. , New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs, Thromb Haemost, vol.104, issue.6, pp.1099-105, 2010.

S. U. Khan, A. Arshad, I. B. Riaz, S. Talluri, F. Nasir et al., Meta-Analysis of the Safety and Efficacy of the Oral Anticoagulant Agents (Apixaban, Rivaroxaban, Dabigatran) in Patients With Acute Coronary Syndrome, Am J Cardiol, vol.121, issue.3, pp.301-308, 2018.

N. Étude, . Du, and . Nacora, nouveaux anticoagulants oraux et risques associés, 2016.

F. Laliberté, M. Cloutier, W. W. Nelson, C. I. Coleman, D. Pilon et al., Realworld comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients, Curr Med Res Opin, vol.30, issue.7, pp.1317-1342, 2014.

R. Sørensen, G. Gislason, C. Torp-pedersen, J. B. Olesen, E. L. Fosbøl et al.,

. Mw, Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study, BMJ Open, vol.3, issue.5, 2013.

B. Slot, K. M. Berge, and E. , Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation, The Cochrane Library

J. Wiley, &. Sons, ;. Ltd, A. T. Cohen, N. R. Hill et al., A systematic review of network meta-analyses among patients with nonvalvular atrial fibrillation: A comparison of efficacy and safety following treatment with direct oral anticoagulants, Int J Cardiol, 2018.

J. Bezin, M. Duong, R. Lassalle, C. Droz, A. Pariente et al., The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology, Pharmacoepidemiol Drug Saf, vol.26, issue.8, pp.954-62, 2017.

G. Moulis, M. Lapeyre-mestre, A. Palmaro, G. Pugnet, J. Montastruc et al., French health insurance databases: What interest for medical research, Rev Med Interne, vol.36, issue.6, pp.411-418, 2015.

C. Becattini, M. Giustozzi, M. G. Ranalli, G. Bogliari, F. Cianella et al., Variation of renal function over time is associated with major bleeding in patients treated with direct oral anticoagulants for atrial fibrillation, J Thromb Haemost JTH, vol.16, issue.5, pp.833-874, 2018.

T. S. Potpara, G. Boriani, and G. Lip, Evaluating adherence to non-vitamin-K antagonist oral anticoagulants in post-approval observational studies of patients with atrial fibrillation, Curr Med Res Opin, vol.33, issue.6, 2017.

X. Yao, N. S. Abraham, G. C. Alexander, W. Crown, V. M. Montori et al., Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation, J Am Heart Assoc, vol.5, issue.2, 2016.